Navigation Links
MSU investigates drug to halt Parkinson's progression
Date:7/29/2011

GRAND RAPIDS, Mich. Researchers from Michigan State University's College of Human Medicine, Van Andel Research Institute and the Translational Genomics Research Institute are investigating a drug that has the potential to not only alleviate Parkinson's symptoms but also halt the disease's progression.

A $400,000 grant from the Michael J. Fox Foundation for Parkinson's Research part of $2.4 million in funding the foundation awarded this week to institutions nationwide will fund the research project.

Researchers are focusing on the drug Fasudil, which is currently approved in Japan to improve blood flow to the brain in stroke victims and has shown similar positive outcomes in U.S. clinical trials.

In 2009, investigators from the Translational Genomics Research Institute in Arizona and Arizona State University reported that a form of Fasudil had the potential to help improve learning and memory and reduce the risk of Alzheimer's disease. Van Andel researchers also recently discovered the potential of the drug in Parkinson's when they were testing various drugs that reduce the toxicity caused by a defective PARK1 gene, a gene implicated in Parkinson's disease.

"The potential of this drug is exciting not only because it could halt disease progression where other treatments only provide symptomatic relief but also because of how quickly it could be made available to patients," said Jeffrey P. MacKeigan, head of Van Andel's Laboratory of Systems Biology and co-investigator on the project with Caryl E. Sortwell of MSU's College of Human Medicine.

"Fasudil has a very favorable safety profile in humans and already is available in Japan as an oral tablet, so we could be seeing clinical trials within two to three years," MacKeigan added.

The development of new drugs is expensive and time-consuming, said Kuldip Dave, associate director of research programs at MJFF.

"In fall 2010, MJFF launched our inaugural repositioning program to address these realities and to attempt to reduce the time and costs involved in finding drugs that could help people living with Parkinson's," Dave said.

The next step in the project is for researchers from MSU to validate the therapeutic use of Fasudil in disease models of Parkinson's. Ultimately, the goal is to determine whether Fasudil has the therapeutic potential to protect and restore degenerating neurons in Parkinson's.

"This collaboration highlights the strength of strategically aligning teams from two research organizations with different skill sets," said MSU's Sortwell, a professor in the Division of Translational Science and Molecular Medicine. "The Van Andel/TGen team has expertise in cell biology and proteomics, while our researchers have extensive experience in Parkinson's disease systems biology and modeling. Together both organizations share the goal of helping those afflicted with Parkinson's to live better lives as a result of their respective research programs."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert

Related medicine news :

1. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
2. Food Safety Law Firm Investigates Major Outbreak of E. coli Linked To Lettuce
3. Thesis investigates characteristics of society using sports activities as research tool
4. UI study investigates variability in mens recall of sexual cues
5. BUSM investigates cellular mechanisms leading to immune response in airway epithelium
6. New genomics research investigates metastatic childhood cancers
7. Herpes Drug Might Also Slow HIV Progression
8. Targeting the blood-brain barrier may delay progression of Alzheimers disease
9. Statins may slow progression of multiple sclerosis, new study finds
10. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
11. Exercise may slow progression of ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Atlanta, GA (PRWEB) , ... February 12, 2016 ... ... and relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards ... categories will be announced at the ISE® Southeast Executive Forum and Awards Gala ...
(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new ... area. The latest campaign focuses on the fight against breast cancer, fundraising for a ... accepted here . , Carmen is a loving single mother of two boys ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. He ... 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New Port ... hundreds of uninsured and underinsured people receive much-needed dental care. , This was ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information ... Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways ... big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Walgreens has committed to provide drug disposal kiosks ... D.C. as part of a program to combat ... advocacy organization As You Sow. Conrad MacKerron , ... on to unneeded drugs because they lack easily accessible collection ... --> Conrad MacKerron , Senior Vice President at As ...
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
Breaking Medicine Technology: